Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

Inclusion Criteria 1. Age ≥ 18 years old at time of signing informed consent 2. Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment a. Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment 3. Able to provide informed consent Exclusion Criteria 1. Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months 2. BMI \<25 kg/m2 at the time of screening 3. Unable to participate in a regular physical exercise program 4. Implanted pacemaker 5. Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study